93 related articles for article (PubMed ID: 17827387)
1. Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.
Barry EV; Clark JJ; Cools J; Roesel J; Gilliland DG
Blood; 2007 Dec; 110(13):4476-9. PubMed ID: 17827387
[TBL] [Abstract][Full Text] [Related]
2. Real-Time NMR Spectroscopy for Studying Metabolism.
Alshamleh I; Krause N; Richter C; Kurrle N; Serve H; Günther UL; Schwalbe H
Angew Chem Int Ed Engl; 2020 Feb; 59(6):2304-2308. PubMed ID: 31730253
[TBL] [Abstract][Full Text] [Related]
3. Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center.
Kennedy A; Patel S; Ramanathan M; Gerber J; Cerny J
Ann Hematol; 2024 Mar; 103(3):1031-1033. PubMed ID: 38195923
[No Abstract] [Full Text] [Related]
4. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
Stone RM; Fischer T; Paquette R; Schiller G; Schiffer CA; Ehninger G; Cortes J; Kantarjian HM; DeAngelo DJ; Huntsman-Labed A; Dutreix C; del Corral A; Giles F
Leukemia; 2012 Sep; 26(9):2061-8. PubMed ID: 22627678
[TBL] [Abstract][Full Text] [Related]
5. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
[TBL] [Abstract][Full Text] [Related]
6. Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
Rummelt C; Gorantla SP; Meggendorfer M; Charlet A; Endres C; Döhner K; Heidel FH; Fischer T; Haferlach T; Duyster J; von Bubnoff N
Leukemia; 2021 Jul; 35(7):2017-2029. PubMed ID: 33149267
[TBL] [Abstract][Full Text] [Related]
7. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Sato T; Yang X; Knapper S; White P; Smith BD; Galkin S; Small D; Burnett A; Levis M
Blood; 2011 Mar; 117(12):3286-93. PubMed ID: 21263155
[TBL] [Abstract][Full Text] [Related]
8. Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine.
Kannampuzha S; Murali R; Gopalakrishnan AV; Mukherjee AG; Wanjari UR; Namachivayam A; George A; Dey A; Vellingiri B
Med Oncol; 2023 Oct; 40(11):323. PubMed ID: 37804361
[TBL] [Abstract][Full Text] [Related]
9. Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia.
Ezelarab HAA; Ali TFS; Abbas SH; Hassan HA; Beshr EAM
BMC Chem; 2023 Jul; 17(1):73. PubMed ID: 37438819
[TBL] [Abstract][Full Text] [Related]
10. Classification of FLT3 inhibitors and SAR analysis by machine learning methods.
Zhao Y; Tian Y; Pang X; Li G; Shi S; Yan A
Mol Divers; 2023 May; ():. PubMed ID: 37142889
[TBL] [Abstract][Full Text] [Related]
11. Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293564
[TBL] [Abstract][Full Text] [Related]
12. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Scholl S; Fleischmann M; Schnetzke U; Heidel FH
Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Eguchi M; Minami Y; Kuzume A; Chi S
Biomedicines; 2020 Jul; 8(8):. PubMed ID: 32722298
[TBL] [Abstract][Full Text] [Related]
15. GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo.
Wang Y; Zhang L; Tang X; Luo J; Tu Z; Jiang K; Ren X; Xu F; Chan S; Li Y; Zhang Z; Ding K
Transl Oncol; 2020 Apr; 13(4):100766. PubMed ID: 32247263
[TBL] [Abstract][Full Text] [Related]
16. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
[TBL] [Abstract][Full Text] [Related]
17. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
[TBL] [Abstract][Full Text] [Related]
18. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Gallogly MM; Lazarus HM; Cooper BW
Ther Adv Hematol; 2017 Sep; 8(9):245-261. PubMed ID: 29051803
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ
Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]